QUARTERLY REPORT

Q3 2026 — Quarterly report

Q3 2026PDF · 32 pages363 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________
FORM 10-Q
__________________________________________________________
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2026
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
Commission File Number: 1-10864
__________________________________________________________
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
__________________________________________________________
Delaware 41-1321939
(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification No.)
1 Health Drive
55344
655 New York Avenue NW
20001	Eden Prairie, Minnesota Washington, DC
(Address of principal executive offices) (Zip Code) (Address of principal executive offices) (Zip Code)
(800) 328-5979
(Registrant’s telephone number, including area code)
_________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $.01 par value UNH New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐
Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 30, 2026, there were 896,022,611 shares of the registrant’s Common Stock, $.01 par value per share outstanding.

-- 1 of 32 --

UNITEDHEALTH GROUP
Table of Contents
Page
Part I. Financial Information
Item 1. Financial Statements (unaudited) ......................................................................................................................... 1
Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025 ............................ 1
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30,
2026 and 2025 .................................................................................................................................................. 2
Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended
September 30, 2026 and 2025........................................................................................................................... 3
Condensed Consolidated Statements of Changes in Equity for the Three and Nine Months Ended September
30, 2026 and 2025............................................................................................................................................. 4
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and
2025 .................................................................................................................................................................. 6
Notes to the Condensed Consolidated Financial Statements................................................................................ 7
1. Basis of Presentation.................................................................................................................................... 7
2. Investments ................................................................................................................................................. 8
3. Fair Value .................................................................................................................................................... 10
4. Medical Costs Payable................................................................................................................................. 11
5. Short-Term Borrowings and Long-Term Debt............................................................................................ 12
6. Shareholders’ Equity.................................................................................................................................... 12
7. Commitments and Contingencies ................................................................................................................ 12
8. Held for Sale and Dispositions .................................................................................................................... 14
9. Segment Financial Information ................................................................................................................... 15
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations .............................. 17
Item 3. Quantitative and Qualitative Disclosures About Market Risk ............................................................................. 27
Item 4. Controls and Procedures....................................................................................................................................... 27
Part II. Other Information
Item 1. Legal Proceedings ................................................................................................................................................ 28
Item 1A. Risk Factors .......................................................................................................................................................... 28
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.............................................................................. 28
Item 5. Other Information................................................................................................................................................. 28
Item 6. Exhibits................................................................................................................................................................. 29
Signatures............................................................................................................................................................................... 30

-- 2 of 32 --

PART I
ITEM 1. FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data) September 30,
2026 December 31,
2025
Assets
Current assets:
Cash and cash equivalents ...................................................................................................................... $ 25,845 $ 24,365
Short-term investments........................................................................................................................... 2,704 3,756
Accounts receivable, net......................................................................................................................... 20,543 23,018
Other current receivables, net................................................................................................................. 27,577 29,697
Prepaid expenses and other current assets.............................................................................................. 8,926 9,746
Total current assets ......................................................................................................................................... 85,595 90,582
Long-term investments................................................................................................................................... 58,064 54,251
Property, equipment and capitalized software, net......................................................................................... 10,950 10,762
Goodwill ......................................................................................................................................................... 112,974 110,499
Other intangible assets, net............................................................................................................................. 20,377 20,474
Other assets..................................................................................................................................................... 24,822 23,013
Total assets .................................................................................................................................................... $ 312,782 $ 309,581
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable............................................................................................................................. $ 39,352 $ 39,337
Accounts payable and accrued liabilities................................................................................................ 39,560 38,032
Short-term borrowings and current maturities of long-term debt........................................................... 5,617 6,069
Unearned revenues ................................................................................................................................. 3,397 3,413
Other current liabilities........................................................................................................................... 27,909 28,046
Total current liabilities.................................................................................................................................... 115,835 114,897
Long-term debt, less current maturities.......................................................................................................... 68,714 72,320
Deferred income taxes .................................................................................................................................... 2,528 2,421
Other liabilities ............................................................................................................................................... 20,160 18,245
Total liabilities................................................................................................................................................ 207,237 207,883
Commitments and contingencies (Note 7)
Redeemable noncontrolling interests.............................................................................................................. 1,416 1,608
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding................... — —
Common stock, $0.01 par value - 3,000 shares authorized; 896 and 906 issued and outstanding......... 9 9
Additional paid-in capital ....................................................................................................................... — 559
Retained earnings ................................................................................................................................... 102,021 95,603
Accumulated other comprehensive loss ................................................................................................. (3,934) (2,061)
Nonredeemable noncontrolling interests ........................................................................................................ 6,033 5,980
Total equity..................................................................................................................................................... 104,129 100,090
Total liabilities, redeemable noncontrolling interests and equity ............................................................ $ 312,782 $ 309,581
See Notes to the Condensed Consolidated Financial Statements
1

-- 3 of 32 --

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended
September 30, Nine Months Ended
September 30,
(in millions, except per share data) 2026 2025 2026 2025
Revenues:
Premiums .......................................................................................................... $ 87,078 $ 88,979 $ 261,595 $ 263,418
Products............................................................................................................. 14,293 13,296 41,378 39,896
Services............................................................................................................. 10,246 9,754 30,043 27,765
Investment and other income............................................................................ 1,077 1,132 3,431 3,273
Total revenues........................................................................................................... 112,694 113,161 336,447 334,352
Operating costs:
Medical costs .................................................................................................... 76,982 79,958 225,829 231,954
Operating costs.................................................................................................. 14,369 15,223 44,027 42,595
Cost of products sold ........................................................................................ 13,707 12,566 39,905 37,975
Depreciation and amortization.......................................................................... 1,073 1,099 3,142 3,244
Total operating costs................................................................................................. 106,131 108,846 312,903 315,768
Earnings from operations....................................................................................... 6,563 4,315 23,544 18,584
Interest expense......................................................................................................... (963) (1,003) (2,880) (3,028)
Loss on sale of subsidiary and subsidiaries held for sale.......................................... (76) (83) (209) (139)
Earnings before income taxes ................................................................................ 5,524 3,229 20,455 15,417
Provision for income taxes........................................................................................ (1,224) (686) (4,004) (2,828)
Net earnings............................................................................................................. 4,300 2,543 16,451 12,589
Earnings attributable to noncontrolling interests ...................................................... (190) (195) (577) (543)
Net earnings attributable to UnitedHealth Group common shareholders........ $ 4,110 $ 2,348 $ 15,874 $ 12,046
Earnings per share attributable to UnitedHealth Group common
shareholders: .......................................................................................................
Basic.................................................................................................................. $ 4.58 $ 2.59 $ 17.58 $ 13.27
Diluted............................................................................................................... $ 4.56 $ 2.59 $ 17.50 $ 13.21
Basic weighted-average number of common shares outstanding....................... 897 906 902 908
Dilutive effect of common share equivalents........................................................ 5 2 4 4
Diluted weighted-average number of common shares outstanding ................... 902 908 906 912
Anti-dilutive shares excluded from the calculation of dilutive effect of common
share equivalents................................................................................................... 11 16 13 12
See Notes to the Condensed Consolidated Financial Statements
2

-- 4 of 32 --

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
September 30, Nine Months Ended
September 30,
(in millions) 2026 2025 2026 2025
Net earnings............................................................................................................. $ 4,300 $ 2,543 $ 16,451 $ 12,589
Other comprehensive (loss) income:
Gross unrealized (losses) gains on investment securities during the period..... (1,821) 535 (2,219) 1,383
Income tax effect............................................................................................... 418 (122) 509 (316)
Total unrealized (losses) gains, net of tax.................................................... (1,403) 413 (1,710) 1,067
Gross reclassification adjustment for net realized losses (gains) included in
net earnings ................................................................................................... 52 (24) 62 (51)
Income tax effect............................................................................................... (12) 6 (14) 12
Total reclassification adjustment, net of tax .............................................. 40 (18) 48 (39)
Foreign currency translation (losses) gains....................................................... (52) (71) (51) 148
Reclassification adjustment for translation gains included in net earnings ...... — — (160) —
Total foreign currency translation (losses) gains ......................................... (52) (71) (211) 148
Other comprehensive (loss) income ....................................................................... (1,415) 324 (1,873) 1,176
Comprehensive income............................................................................................. 2,885 2,867 14,578 13,765
Comprehensive income attributable to noncontrolling interests .............................. (190) (195) (577) (543)
Comprehensive income attributable to UnitedHealth Group common
shareholders......................................................................................................... $ 2,695 $ 2,672 $ 14,001 $ 13,222
See Notes to the Condensed Consolidated Financial Statements
3

-- 5 of 32 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common Stock
Additional
Paid-In
Capital Retained
Earnings
Accumulated Other
Comprehensive Loss
Nonredeemable
Noncontrolling
Interests Total
Equity
Three months ended September 30,
(in millions) Shares Amount
Net
Unrealized
(Losses)
Gains on
Investments
Foreign
Currency
Translation
(Losses)
Gains
Balance at June 30, 2026 ................... 905 $ 9 $ — $ 100,957 $ (1,377) $ (1,142) $ 6,066 $ 104,513
Net earnings ....................................... 4,110 174 4,284
Other comprehensive loss.................. (1,363) (52) (1,415)
Issuances of common stock, and
related tax effects ........................... 1 — 216 216
Share-based compensation................. 223 223
Common share repurchases ............... (10) — (451) (968) (1,419)
Cash dividends paid on common
shares ($2.32 per share) ................. (2,078) (2,078)
Redeemable noncontrolling interests
fair value and other adjustments .... 12 12
Acquisition and other adjustments of
nonredeemable noncontrolling
interests .......................................... (15) (15)
Distribution to nonredeemable
noncontrolling interests.................. (192) (192)
Balance at September 30, 2026.......... 896 $ 9 $ — $ 102,021 $ (2,740) $ (1,194) $ 6,033 $ 104,129
Balance at June 30, 2025 ................... 905 $ 9 $ — $ 97,250 $ (1,593) $ (942) $ 5,745 $ 100,469
Net earnings ....................................... 2,348 167 2,515
Other comprehensive income (loss)... 395 (71) 324
Issuances of common stock, and
related tax effects ........................... 1 — 241 241
Share-based compensation................. 214 214
Common share repurchases ............... — — 1 (1) —
Cash dividends paid on common
shares ($2.21 per share) ................. (2,002) (2,002)
Redeemable noncontrolling interests
fair value and other adjustments .... (62) (62)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests .......................................... 34 34
Distribution to nonredeemable
noncontrolling interests.................. (164) (164)
Balance at September 30, 2025.......... 906 $ 9 $ 394 $ 97,595 $ (1,198) $ (1,013) $ 5,782 $ 101,569
See Notes to the Condensed Consolidated Financial Statements
4

-- 6 of 32 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common Stock
Additional
Paid-In
Capital Retained
Earnings
Accumulated Other
Comprehensive Loss
Nonredeemable
Noncontrolling
Interests Total
Equity
Nine months ended September 30,
(in millions) Shares Amount
Net
Unrealized
(Losses)
Gains on
Investments
Foreign
Currency
Translation
(Losses)
Gains
Balance at January 1, 2026 ................ 906 $ 9 $ 559 $ 95,603 $ (1,078) $ (983) $ 5,980 $ 100,090
Net earnings ....................................... 15,874 509 16,383
Other comprehensive loss.................. (1,662) (211) (1,873)
Issuances of common stock, and
related tax effects ........................... 4 — 410 410
Share-based compensation................. 813 813
Common share repurchases ............... (14) — (1,861) (3,286) (5,147)
Cash dividends paid on common
shares ($6.85 per share) ................. (6,170) (6,170)
Redeemable noncontrolling interests
fair value and other adjustments .... 79 79
Acquisition and other adjustments of
nonredeemable noncontrolling
interests .......................................... 79 79
Distribution to nonredeemable
noncontrolling interests.................. (535) (535)
Balance at September 30, 2026.......... 896 $ 9 $ — $ 102,021 $ (2,740) $ (1,194) $ 6,033 $ 104,129
Balance at January 1, 2025 ................ 915 $ 9 $ — $ 96,036 $ (2,226) $ (1,161) $ 5,610 $ 98,268
Net earnings ....................................... 12,046 464 12,510
Other comprehensive income ............ 1,028 148 1,176
Issuances of common stock, and
related tax effects ........................... 3 — 620 620
Share-based compensation................. 805 805
Common share repurchases ............... (12) — (954) (4,573) (5,527)
Cash dividends paid on common
shares ($6.52 per share) ................. (5,914) (5,914)
Redeemable noncontrolling interests
fair value and other adjustments .... (77) (77)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests .......................................... 209 209
Distribution to nonredeemable
noncontrolling interests.................. (501) (501)
Balance at September 30, 2025.......... 906 $ 9 $ 394 $ 97,595 $ (1,198) $ (1,013) $ 5,782 $ 101,569
See Notes to the Condensed Consolidated Financial Statements
5

-- 7 of 32 --

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
September 30,
(in millions) 2026 2025
Operating activities
Net earnings ............................................................................................................................................................. $ 16,451 $ 12,589
Noncash items:
Depreciation and amortization......................................................................................................................... 3,142 3,244
Deferred income taxes ..................................................................................................................................... 466 (1,019)
Share-based compensation............................................................................................................................... 843 795
Loss on sale of subsidiary and subsidiaries held for sale................................................................................. 209 139
Other, net.......................................................................................................................................................... (351) 64
Net change in other operating items, net of effects from acquisitions and dispositions:
Accounts receivable ......................................................................................................................................... 2,560 65
Other assets ...................................................................................................................................................... 1,736 (3,105)
Medical costs payable...................................................................................................................................... (49) 6,178
Accounts payable and other liabilities ............................................................................................................. 88 (417)
Unearned revenues........................................................................................................................................... (8) 56
Cash flows from operating activities ....................................................................................................................... 25,087 18,589
Investing activities
Purchases of investments ......................................................................................................................................... (16,545) (12,805)
Sales of investments................................................................................................................................................. 5,294 7,945
Maturities of investments......................................................................................................................................... 6,765 6,517
Cash paid for acquisitions and other transactions, net of cash assumed.................................................................. (1,538) (4,436)
Purchases of property, equipment and capitalized software.................................................................................... (2,421) (2,674)
Repayments of care provider loans - cyberattack .................................................................................................... 282 1,543
Originations and purchases of loans ........................................................................................................................ (4,533) (3,282)
Repayments and maturities of loans ........................................................................................................................ 2,301 994
Cash received from dispositions and other strategic transactions, net..................................................................... 1,113 214
Other, net.................................................................................................................................................................. 464 (90)
Cash flows used for investing activities................................................................................................................... (8,818) (6,074)
Financing activities
Common share repurchases ..................................................................................................................................... (5,031) (5,545)
Cash dividends paid ................................................................................................................................................. (6,170) (5,914)
Proceeds from common stock issuances.................................................................................................................. 599 803
Repayments of long-term debt................................................................................................................................. (3,650) (2,000)
Proceeds from short-term borrowings, net............................................................................................................... 575 1,469
Proceeds from issuance of long-term debt............................................................................................................... — 2,969
Customer funds administered .................................................................................................................................. (743) (1,792)
Other, net.................................................................................................................................................................. (613) (603)
Cash flows used for financing activities .................................................................................................................. (15,033) (10,613)
Effect of exchange rate changes on cash and cash equivalents ............................................................................... (11) 25
Increase in cash and cash equivalents, including cash within businesses held for sale................................... 1,225 1,927
Net change in cash within businesses held for sale ................................................................................................. 255 (29)
Net increase in cash and cash equivalents ............................................................................................................... 1,480 1,898
Cash and cash equivalents, beginning of period ................................................................................................. 24,365 25,312
Cash and cash equivalents, end of period............................................................................................................ $ 25,845 $ 27,210
See Notes to the Condensed Consolidated Financial Statements
6

-- 8 of 32 --

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”)
is a health care and well-being company with a mission to help people live healthier lives and help make the health system work
better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are
working to help build a modern, high-performing health system through improved access, affordability, outcomes and
experiences for the individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted
Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries, including variable
interest entities. Intercompany accounts and transactions have been eliminated. The year-end Condensed Consolidated Balance
Sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with
the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote
disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements.
Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial
Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC (2025 10-K). The accompanying Condensed
Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial
statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and
judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and
goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve
matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is
included in earnings in the period in which the estimate is adjusted.
Revenues - Products and Services
As of September 30, 2026 and December 31, 2025, accounts receivable related to products and services were $9.6 billion and
$9.7 billion, respectively. As of September 30, 2026, revenue expected to be recognized in any future year related to remaining
performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less,
contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance
obligations, was $10.2 billion, of which more than half is expected to be recognized in the next three years.
Receivables Financing Facility
The Company has a $2.2 billion 364-day uncommitted revolving receivables financing facility under which certain receivables
may be sold to financial institutions. During the three and nine months ended September 30, 2026, the Company sold $2.8
billion and $5.9 billion of receivables under the receivables financing facility. As of September 30, 2026, $5.5 billion was
collected from counterparties, with $1.5 billion not yet remitted to financial institutions. During the nine months ended
September 30, 2026, the Company also remitted $2.0 billion to financial institutions related to receivables sold in 2025. This
was comprised of $1.0 billion collected but not remitted in 2025 and an additional $1.0 billion collected in 2026. The loss on
discounted receivables was immaterial for the three and nine months ended September 30, 2026.
Net Portfolio Divestitures and Restructuring and Other Actions
Net Portfolio Divestitures
In the fourth quarter of 2025, the Company took various actions as a result of a strategic review of its assets and businesses
aimed at advancing and scaling its core operations, including the value-based care business at Optum Health. For the three and
nine months ended September 30, 2026, these actions resulted in a gain of $224 million and $415 million, respectively. For the
three months ended September 30, 2026, these actions included net gains on businesses held for sale and a gain on an asset sale,
partially offset by incremental losses on our remaining South American operations. For the nine months ended September 30,
2026, these actions included a net gain on the sales of businesses previously classified as held for sale as of December 31, 2025
and a gain on an asset sale, partially offset by incremental losses on businesses held for sale. By segment, third quarter impacts
consisted of net gains of $141 million and $85 million at UnitedHealthcare and Optum Health, respectively, partially offset by
net losses of $2 million at Optum Insight. Year-to-date impacts consisted of gains of $522 million, $141 million and $8 million
at Optum Insight, UnitedHealthcare and Optum Rx, respectively, partially offset by a net loss of $256 million at Optum Health.
7

-- 9 of 32 --

Gains and losses on portfolio actions were recorded within operating costs on the Condensed Consolidated Statements of
Operations.
Restructuring and Other Actions
For the three and nine months ended September 30, 2026, restructuring and other actions included a net decrease in loss
contract reserves of $95 million and $282 million, respectively, and net valuation (losses) gains on equity securities of $(21)
million and $39 million, respectively, while the year-to-date results also included a $400 million contribution to the United
Health Foundation funded by the cash gain on the disposition of an Optum Insight business. By segment, the third quarter
impacts were $62 million and $12 million at Optum Health and Optum Insight, respectively. Year-to-date impacts were $327
million at Optum Insight, partially offset by $248 million at Optum Health. For the three months ended September 30, 2026,
these items decreased investment and other income by $21 million and decreased medical costs by $95 million. For the nine
months ended September 30, 2026, these items increased operating costs by $415 million, partially offset by a $54 million
increase to investment and other income and $282 million decrease in medical costs, as reflected on the Condensed
Consolidated Statements of Operations.
2. Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses Fair
Value
September 30, 2026
Debt securities - available-for-sale:
U.S. government and agency obligations ............................. $ 3,416 $ — $ (256) $ 3,160
State and municipal obligations............................................ 5,169 1 (466) 4,704
Corporate obligations ........................................................... 29,627 38 (1,447) 28,218
U.S. agency mortgage-backed securities.............................. 12,134 — (1,256) 10,878
Non-U.S. agency mortgage-backed securities...................... 3,495 — (167) 3,328
Total debt securities - available-for-sale ...................................... 53,841 39 (3,592) 50,288
Debt securities - held-to-maturity:
U.S. government and agency obligations ............................. 445 — (3) 442
State and municipal obligations............................................ 25 — (4) 21
Corporate obligations ........................................................... 3 — — 3
Total debt securities - held-to-maturity ......................................... 473 — (7) 466
Total debt securities...................................................................... $ 54,314 $ 39 $ (3,599) $ 50,754
December 31, 2025
Debt securities - available-for-sale:
U.S. government and agency obligations ............................. $ 4,086 $ 2 $ (156) $ 3,932
State and municipal obligations............................................ 6,533 24 (232) 6,325
Corporate obligations ........................................................... 25,927 159 (540) 25,546
U.S. agency mortgage-backed securities.............................. 10,284 33 (598) 9,719
Non-U.S. agency mortgage-backed securities...................... 2,748 11 (99) 2,660
Total debt securities - available-for-sale ...................................... 49,578 229 (1,625) 48,182
Debt securities - held-to-maturity:
U.S. government and agency obligations ............................. 461 2 (1) 462
State and municipal obligations............................................ 26 — (2) 24
Corporate obligations ........................................................... 3 — — 3
Total debt securities - held-to-maturity ........................................ 490 2 (3) 489
Total debt securities...................................................................... $ 50,068 $ 231 $ (1,628) $ 48,671
8

-- 10 of 32 --

The Company held $6.0 billion and $5.5 billion of equity securities as of September 30, 2026 and December 31, 2025,
respectively. The Company’s investments in equity securities primarily consist of venture investments and employee savings
plan related investments. The carrying values of equity securities held at fair value on a non-recurring basis were $3.7 billion
and $3.3 billion, including cumulative net unrealized gains of $917 million and $846 million, as of September 30, 2026 and
December 31, 2025, respectively.
Additionally, the Company’s investments included $4.0 billion and $3.8 billion of equity method investments primarily in
operating businesses in the health care sector as of September 30, 2026 and December 31, 2025, respectively. The allowance
for credit losses on held-to-maturity securities at September 30, 2026 and December 31, 2025 was not material.
The amortized cost and fair value of debt securities as of September 30, 2026, by contractual maturity, were as follows:
Available-for-Sale Held-to-Maturity
(in millions) Amortized
Cost Fair
Value Amortized
Cost Fair
Value
Due in one year or less ..................................................................................................... $ 2,783 $ 2,769 $ 314 $ 314
Due after one year through five years .............................................................................. 13,733 13,099 137 135
Due after five years through ten years.............................................................................. 13,309 12,420 5 4
Due after ten years............................................................................................................ 8,387 7,794 17 13
U.S. agency mortgage-backed securities.......................................................................... 12,134 10,878 — —
Non-U.S. agency mortgage-backed securities.................................................................. 3,495 3,328 — —
Total debt securities.......................................................................................................... $ 53,841 $ 50,288 $ 473 $ 466
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that
individual securities have been in a continuous unrealized loss position were as follows:
Less Than 12 Months 12 Months or Greater Total
(in millions) Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses
September 30, 2026
U.S. government and agency obligations.................. $ 1,394 $ (44) $ 1,570 $ (212) $ 2,964 $ (256)
State and municipal obligations................................. 1,855 (125) 2,701 (341) 4,556 (466)
Corporate obligations................................................. 18,795 (725) 6,861 (722) 25,656 (1,447)
U.S. agency mortgage-backed securities ................... 6,290 (376) 4,575 (880) 10,865 (1,256)
Non-U.S. agency mortgage-backed securities ........... 1,949 (55) 1,052 (112) 3,001 (167)
Total debt securities - available-for-sale.................... $ 30,283 $ (1,325) $ 16,759 $ (2,267) $ 47,042 $ (3,592)
December 31, 2025
U.S. government and agency obligations .................. $ 500 $ (4) $ 2,339 $ (152) $ 2,839 $ (156)
State and municipal obligations................................. 523 (8) 4,342 (224) 4,865 (232)
Corporate obligations................................................. 2,661 (16) 10,399 (524) 13,060 (540)
U.S. agency mortgage-backed securities ................... 346 (1) 6,665 (597) 7,011 (598)
Non-U.S. agency mortgage-backed securities ........... 184 (1) 1,355 (98) 1,539 (99)
Total debt securities - available-for-sale.................... $ 4,214 $ (30) $ 25,100 $ (1,595) $ 29,314 $ (1,625)
The Company’s unrealized losses from debt securities as of September 30, 2026 were generated from approximately 38,000
positions out of a total of 42,000 positions. The Company believes that it will timely collect the principal and interest due on its
debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate
increases rather than unfavorable changes in the credit quality of these securities. At each reporting period, the Company
evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than
its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the
issuers, noting no significant credit deterioration since purchase. As of September 30, 2026, the Company did not have the
intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these
losses to be temporary. The allowance for credit losses on available-for-sale debt securities at September 30, 2026 and
December 31, 2025 was not material.
9

-- 11 of 32 --

3. Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values
disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of
three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy
classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in
Part II, Item 8, “Financial Statements and Supplementary Data” in the 2025 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair
value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and
Carrying
Value
September 30, 2026
Cash and cash equivalents.............................................................................. $ 16,386 $ 9,459 $ — $ 25,845
Debt securities - available-for-sale:
U.S. government and agency obligations............................................... 3,134 26 — 3,160
State and municipal obligations ............................................................. — 4,704 — 4,704
Corporate obligations ............................................................................. — 27,686 532 28,218
U.S. agency mortgage-backed securities................................................ — 10,878 — 10,878
Non-U.S. agency mortgage-backed securities ....................................... — 3,328 — 3,328
Total debt securities - available-for-sale ........................................................ 3,134 46,622 532 50,288
Equity securities ............................................................................................. 2,200 — 74 2,274
Loan receivables............................................................................................. — — 729 729
Total assets at fair value ................................................................................. $ 21,720 $ 56,081 $ 1,335 $ 79,136
Percentage of total assets at fair value ........................................................... 27 % 71 % 2 % 100 %
December 31, 2025
Cash and cash equivalents.............................................................................. $ 19,848 $ 4,517 $ — $ 24,365
Debt securities - available-for-sale:
U.S. government and agency obligations............................................... 3,778 154 — 3,932
State and municipal obligations ............................................................. — 6,325 — 6,325
Corporate obligations ............................................................................. — 25,123 423 25,546
U.S. agency mortgage-backed securities................................................ — 9,719 — 9,719
Non-U.S. agency mortgage-backed securities ....................................... — 2,660 — 2,660
Total debt securities - available-for-sale ........................................................ 3,778 43,981 423 48,182
Equity securities ............................................................................................. 2,083 20 67 2,170
Loan receivables............................................................................................. — — 882 882
Total assets at fair value ................................................................................. $ 25,709 $ 48,518 $ 1,372 $ 75,599
Percentage of total assets at fair value ........................................................... 34 % 64 % 2 % 100 %
There were no transfers in or out of Level 3 financial assets or liabilities during the nine months ended September 30, 2026 or
2025.
10

-- 12 of 32 --

The following table presents a summary of fair value measurements by level and carrying values for certain financial
instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total
Carrying
Value
September 30, 2026
Debt securities - held-to-maturity ........................................ $ 445 $ 21 $ — $ 466 $ 473
Loan receivables .................................................................. — 1,912 8,513 10,425 10,730
Long-term debt and other financing obligations.................. — 63,481 — 63,481 71,391
December 31, 2025
Debt securities - held-to-maturity ........................................ $ 463 $ 26 $ — $ 489 $ 490
Loan receivables .................................................................. — 1,700 6,923 8,623 8,860
Long-term debt and other financing obligations.................. — 72,143 — 72,143 76,140
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are
subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. The assets
and liabilities within businesses held for sale as of September 30, 2026 were measured at the lower of carrying value or fair
value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from
Company-specific information, market conditions and third-party indications. There were no significant fair value adjustments
for assets and liabilities recorded during the nine months ended September 30, 2026 or 2025.
4. Medical Costs Payable
The following table shows the components of the change in medical costs payable for the nine months ended September 30:
(in millions) 2026 2025
Medical costs payable, beginning of period ........................................................................................................ $ 39,337 $ 34,224
Acquisitions (dispositions), net — 20
Reported medical costs:
Current year ................................................................................................................................................. 227,600 231,734
Prior years.................................................................................................................................................... (1,440) (30)
Changes in premium deficiency and loss contract reserves ........................................................................ (331) 250
Total reported medical costs................................................................................................................................ 225,829 231,954
Medical payments:
Payments for current year............................................................................................................................ (191,587) (195,548)
Payments for prior years.............................................................................................................................. (34,383) (30,453)
Total medical payments....................................................................................................................................... (225,970) (226,001)
Change in medical costs payable included within businesses held for sale ........................................................ 156 (16)
Medical costs payable, end of period .................................................................................................................. $ 39,352 $ 40,181
For the nine months ended September 30, 2026, prior years’ medical cost reserve development was driven by a favorable
respiratory illness season along with various other individually insignificant factors. For the nine months ended September 30,
2025, prior years’ medical cost reserve development did not include any individually significant factors. Medical costs payable
included reserves for claims incurred by consumers but not yet reported to the Company of $26.7 billion at both September 30,
2026 and December 31, 2025.
11

-- 13 of 32 --

5. Short-Term Borrowings and Long-Term Debt
As of September 30, 2026, the Company had $2.9 billion of commercial paper outstanding, with a weighted-average annual
interest rate of 3.9%. For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see
Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary
Data” in the 2025 10-K.
6. Shareholders’ Equity
Dividends
In June 2026, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual
rate of $9.28 compared to $8.84 per share which the Company had paid since June 2025. Declaration and payment of future
quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions
change.
The following table provides details of the Company’s 2026 dividend payments:
Payment Date Amount per Share Total Amount Paid
(in millions)
March 17 .................................................................................................................... $ 2.21 $ 2,005
June 23........................................................................................................................ 2.32 2,087
September 22.............................................................................................................. 2.32 2,078
Forward Share Repurchase Contracts
During the nine months ended September 30, 2026, the Company entered into forward contracts with a counterparty to
repurchase up to $2.0 billion of its common stock, which were settled on July 1, 2026. During the nine months ended
September 30, 2026, the counterparty completed the purchase of 6.4 million shares at an average price of $312.73 per share.
The calculation of basic and diluted earnings per share includes an immaterial reduction to net earnings attributable to
UnitedHealth Group common shareholders for undistributed earnings attributable to the shares held by the counterparty for the
nine months ended September 30, 2026.
Share Repurchase Program
In November 2026, the Company’s Board of Directors amended the Company’s share repurchase program to authorize the
repurchase of up to 50 million shares of Common Stock, in addition to all remaining shares authorized to be repurchased under
the Board’s 2024 renewal of the program.
7. Commitments and Contingencies
Legal Matters
The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits
brought by members, care providers, consumer advocacy organizations, customers, shareholders and regulators, relating to the
Company’s businesses, including management and administration of health benefit plans and other services. These matters
include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to
health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of
costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where
the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present
novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the
early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to
estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be
incurred.
12

-- 14 of 32 --

Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These
include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services
(CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General (OIG),
the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade
Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service
(IRS), the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation,
the Consumer Financial Protection Bureau, the Defense Contract Audit Agency, the Food and Drug Administration and other
governmental authorities. Similarly, the Company’s international businesses are also subject to investigations, audits and
reviews by applicable foreign governments. The Company has also been responding to subpoenas, information requests and
investigations from governmental entities. The Company can provide no assurance as to the scope and outcome of these matters
and no assurance as to whether its business, financial condition or results of operations will be materially adversely affected.
Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters,
compliance with coding and other requirements under the Medicare risk-adjustment model. CMS and OIG have selected certain
of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and
supporting documentation maintained by health care providers, and such audits may result in retrospective adjustments to
payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the
Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15,
2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. In March 2025, a
Special Master appointed by the court issued a report recommending that the court enter summary judgment in the Company’s
favor on all remaining claims. In April 2025, the DOJ filed a motion asking the court to reject the Special Master’s report. The
Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.
Income Taxes - Internal Revenue Service Exams
On March 6, 2026, the Company received Notices of Proposed Adjustment (“NOPAs”) from the IRS for transactions
undertaken during the 2017 through 2020 tax years involving intercompany transfer pricing with a foreign subsidiary. The IRS
is seeking to significantly increase taxable income for each of the applicable periods and could also seek similar adjustments for
subsequent years after 2020. The Company disagrees with the IRS’s proposed adjustments, believes its tax positions are
properly supported, and intends to vigorously contest the position taken by the IRS and pursue all available administrative and
judicial remedies. As of September 30, 2026, the Company believes its reserves for uncertain tax positions are adequate based
on current available information. For more information on the Company’s income taxes, see Note 9 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2025 10-
K.
Other Commitments
On July 2, 2026, the Company completed an acquisition for $3.0 billion, with $1.5 billion of cash and the remaining $1.5
billion payable within one year. The payable was outstanding as of September 30, 2026.
13

-- 15 of 32 --

8. Held for Sale and Dispositions
In the fourth quarter of 2025, the Company entered into an agreement to sell its remaining South American operations, which is
expected to close in the fourth quarter of 2026, subject to regulatory and other customary closing conditions. Losses related to
this transaction are included within loss on sale of subsidiary and subsidiaries held for sale on the Condensed Consolidated
Statements of Operations as they relate to the strategic exit of South American markets and include significant losses related to
foreign currency translation effects.
The Company initiated various other dispositions in the fourth quarter of 2025. Dispositions not yet closed as of September 30,
2026 are classified as held for sale. Losses related to these actions are included within operating costs on the Condensed
Consolidated Statements of Operations.
The assets and liabilities of the held for sale disposal groups as of September 30, 2026, were as follows:
(in millions) South American
Businesses Other Businesses
Assets
Cash and cash equivalents .............................................................................................................. $ 275 $ 43
Accounts receivable and other current assets ................................................................................. 811 92
Property, equipment and capitalized software ................................................................................ 865 129
Goodwill ......................................................................................................................................... 168 42
Other intangible assets .................................................................................................................... 251 365
Other long-term assets .................................................................................................................... 323 228
Remeasurement of assets of businesses held for sale to fair value less cost to sell(1)..................... (1,732) (450)
Total assets ................................................................................................................................ $ 961 $ 449
Liabilities
Medical costs payable..................................................................................................................... $ 233 $ —
Accounts payable and other current liabilities ................................................................................ 392 170
Other long-term liabilities............................................................................................................... 362 169
Total liabilities........................................................................................................................... $ 987 $ 339
(1) Includes the effect of $964 million of cumulative foreign currency translation losses and $281 million of noncontrolling interests for the
South American businesses held for sale.
During the nine months ended September 30, 2026, the Company completed dispositions of businesses that were classified as
held for sale in the fourth quarter of 2025 for $1.1 billion of cash. The businesses held assets of $1.2 billion, liabilities of $445
million and had cumulative foreign currency translation gains of $160 million. As a result of the dispositions, the Company
recorded a net gain of $211 million, which was included within operating costs on the Condensed Consolidated Statements of
Operations, with a gain of $525 million at Optum Insight and an incremental loss of $314 million at Optum Health. The
Company contributed $400 million of the proceeds from the disposition within Optum Insight to the United Health Foundation.
14

-- 16 of 32 --

9. Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more
information on the Company’s segments, see Part I, Item 1, “Business” and Note 14 of Notes to the Consolidated Financial
Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2025 10-K.
2026 Business Realignment
On January 1, 2026, the Company realigned certain businesses to respond to changes in the markets it serves and the
opportunities that are emerging as the health system evolves. Optum Financial, including Optum Bank, which was historically
included in Optum Health is now included in Optum Insight. The Company’s reportable segments remain unchanged, with
prior period segment financial information recast to conform to the 2026 presentation.
The following tables present reportable segment financial information:
Optum
(in millions) UnitedHealthcare Optum
Health (b) Optum
Insight (b) Optum
Rx Optum
Eliminations (b) Optum Corporate and
Eliminations Consolidated
Three Months Ended September 30,
2026
Revenues - unaffiliated customers:.........
Premiums ....................................... $ 83,028 $ 4,050 $ — $ — $ — $ 4,050 $ — $ 87,078
Products ......................................... — 62 45 14,186 — 14,293 — 14,293
Services.......................................... 2,765 4,463 1,597 1,421 — 7,481 — 10,246
Total revenues - unaffiliated customers.. 85,793 8,575 1,642 15,607 — 25,824 — 111,617
Total revenues - affiliated customers...... — 14,180 3,496 24,271 (1,428) 40,519 (40,519) —
Investment and other income.................. 537 155 336 49 — 540 — 1,077
Total revenues......................................... $ 86,330 $ 22,910 $ 5,474 $ 39,927 $ (1,428) $ 66,883 $ (40,519) $ 112,694
Total operating costs (a) ......................... $ 83,499 $ 22,175 $ 4,195 $ 38,209 $ (1,428) $ 63,151 $ (40,519) $ 106,131
Earnings from operations........................ $ 2,831 $ 735 $ 1,279 $ 1,718 $ — $ 3,732 $ — $ 6,563
Interest expense....................................... — — — — — — (963) (963)
Loss on sale of subsidiary and
subsidiaries held for sale .................... (76) — — — — — — (76)
Earnings before income taxes................. $ 2,755 $ 735 $ 1,279 $ 1,718 $ — $ 3,732 $ (963) $ 5,524
Total assets.............................................. $ 125,223 $ 72,089 $ 67,213 $ 57,840 $ (492) $ 196,650 $ (9,091) $ 312,782
Purchases of property, equipment and
capitalized software............................ 159 201 394 105 — 700 — 859
Depreciation and Amortization............... 195 253 439 186 — 878 — 1,073
Three Months Ended September 30,
2025
Revenues - unaffiliated customers:.........
Premiums ....................................... $ 83,924 $ 5,055 $ — $ — $ — $ 5,055 $ — $ 88,979
Products ......................................... — 61 45 13,190 — 13,296 — 13,296
Services.......................................... 2,578 4,255 1,678 1,243 — 7,176 — 9,754
Total revenues - unaffiliated customers.. 86,502 9,371 1,723 14,433 — 25,527 — 112,029
Total revenues - affiliated customers...... — 15,811 3,324 25,195 (1,244) 43,086 (43,086) —
Investment and other income.................. 568 240 273 51 — 564 — 1,132
Total revenues......................................... $ 87,070 $ 25,422 $ 5,320 $ 39,679 $ (1,244) $ 69,177 $ (43,086) $ 113,161
Total operating costs (a) ......................... $ 85,265 $ 25,381 $ 4,400 $ 38,130 $ (1,244) $ 66,667 $ (43,086) $ 108,846
Earnings from operations........................ $ 1,805 $ 41 $ 920 $ 1,549 $ — $ 2,510 $ — $ 4,315
Interest expense....................................... — — — — — — (1,003) (1,003)
Loss on sale of subsidiary and
subsidiaries held for sale .................... (83) — — — — — — (83)
Earnings before income taxes................. $ 1,722 $ 41 $ 920 $ 1,549 $ — $ 2,510 $ (1,003) $ 3,229
Total assets.............................................. $ 130,492 $ 73,964 $ 60,777 $ 62,528 $ — $ 197,269 $ (12,492) $ 315,269
Purchases of property, equipment and
capitalized software............................ 238 265 284 103 — 652 — 890
Depreciation and Amortization............... 221 274 394 210 — 878 — 1,099
(a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable for each
reportable segment.
(b) Prior period amounts have been recast to reflect the realignment of Optum Financial.
15

-- 17 of 32 --

Optum
(in millions) UnitedHealthcare Optum
Health (b) Optum
Insight (b) Optum
Rx Optum
Eliminations (b) Optum Corporate and
Eliminations Consolidated
Nine Months Ended September 30,
2026
Revenues - unaffiliated customers:.........
Premiums ....................................... $ 248,627 $ 12,968 $ — $ — $ — $ 12,968 $ — $ 261,595
Products ......................................... — 181 135 41,062 — 41,378 — 41,378
Services.......................................... 8,294 13,172 4,734 3,843 — 21,749 — 30,043
Total revenues - unaffiliated customers.. 256,921 26,321 4,869 44,905 — 76,095 — 333,016
Total revenues - affiliated customers...... — 43,531 10,170 68,911 (4,152) 118,460 (118,460) —
Investment and other income.................. 1,691 639 962 139 — 1,740 — 3,431
Total revenues......................................... $ 258,612 $ 70,491 $ 16,001 $ 113,955 $ (4,152) $ 196,295 $ (118,460) $ 336,447
Total operating costs (a) ......................... $ 246,145 $ 67,425 $ 12,390 $ 109,555 $ (4,152) $ 185,218 $ (118,460) $ 312,903
Earnings from operations........................ $ 12,467 $ 3,066 $ 3,611 $ 4,400 $ — $ 11,077 $ — $ 23,544
Interest expense....................................... — — — — — — (2,880) (2,880)
Loss on sale of subsidiary and
subsidiaries held for sale .................... (209) — — — — — — (209)
Earnings before income taxes................. $ 12,258 $ 3,066 $ 3,611 $ 4,400 $ — $ 11,077 $ (2,880) $ 20,455
Total assets.............................................. $ 125,223 $ 72,089 $ 67,213 $ 57,840 $ (492) $ 196,650 $ (9,091) $ 312,782
Purchases of property, equipment and
capitalized software............................ 570 595 991 265 — 1,851 — 2,421
Depreciation and Amortization............... 589 759 1,245 549 — 2,553 — 3,142
Nine Months Ended September 30,
2025
Revenues - unaffiliated customers:.........
Premiums ....................................... $ 248,456 $ 14,962 $ — $ — $ — $ 14,962 $ — $ 263,418
Products ......................................... — 191 133 39,572 — 39,896 — 39,896
Services.......................................... 7,665 11,660 5,010 3,430 — 20,100 — 27,765
Total revenues - unaffiliated customers.. 256,121 26,813 5,143 43,002 — 74,958 — 331,079
Total revenues - affiliated customers...... — 47,466 9,683 70,122 (3,546) 123,725 (123,725) —
Investment and other income.................. 1,669 705 753 146 — 1,604 — 3,273
Total revenues......................................... $ 257,790 $ 74,984 $ 15,579 $ 113,270 $ (3,546) $ 200,287 $ (123,725) $ 334,352
Total operating costs (a) ......................... $ 248,684 $ 73,103 $ 12,290 $ 108,962 $ (3,546) $ 190,809 $ (123,725) $ 315,768
Earnings from operations........................ $ 9,106 $ 1,881 $ 3,289 $ 4,308 $ — $ 9,478 $ — $ 18,584
Interest expense....................................... — — — — — — (3,028) (3,028)
Loss on sale of subsidiary and
subsidiaries held for sale .................... (139) — — — — — — (139)
Earnings before income taxes................. $ 8,967 $ 1,881 $ 3,289 $ 4,308 $ — $ 9,478 $ (3,028) $ 15,417
Total assets.............................................. $ 130,492 $ 73,964 $ 60,777 $ 62,528 $ — $ 197,269 $ (12,492) $ 315,269
Purchases of property, equipment and
capitalized software............................ 626 821 941 286 — 2,048 — 2,674
Depreciation and Amortization............... 661 791 1,155 637 — 2,583 — 3,244
(a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable for each
reportable segment.
(b) Prior period amounts have been recast to reflect the realignment of Optum Financial.
16

-- 18 of 32 --

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and
Notes and with our 2025 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8,
“Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms
“UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of
Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and
Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic
conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and
uncertainties that may cause our actual results to differ materially from the expectations expressed or implied in the forward-
looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our
2025 10-K and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make
the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare —
are working to help build a modern, high-performing health system through improved access, affordability, outcomes and
experiences for the individuals and organizations we are privileged to serve.
We have four reportable segments:
• Optum Health;
• Optum Insight;
• Optum Rx; and
• UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement
and UnitedHealthcare Community & State.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” in our 2025 10-K and additional information on our segments
can be found in this Item 2 and in Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item
1 of this report.
Net Portfolio Divestitures and Restructuring and Other Actions
Net Portfolio Divestitures
In the fourth quarter of 2025, the Company took various actions as a result of a strategic review of its assets and businesses
aimed at advancing and scaling its core operations, including the value-based care business at Optum Health. For the three and
nine months ended September 30, 2026, these actions resulted in a gain of $224 million and $415 million, respectively. For the
three months ended September 30, 2026, these actions included net gains on businesses held for sale and a gain on an asset sale,
partially offset by incremental losses on our remaining South American operations. For the nine months ended September 30,
2026, these actions included a net gain on the sales of businesses previously classified as held for sale as of December 31, 2025
and a gain on an asset sale, partially offset by incremental losses on businesses held for sale. By segment, third quarter impacts
consisted of net gains of $141 million and $85 million at UnitedHealthcare and Optum Health, respectively, partially offset by
net losses of $2 million at Optum Insight. Year-to-date impacts consisted of gains of $522 million, $141 million and $8 million
at Optum Insight, UnitedHealthcare and Optum Rx, respectively, partially offset by a net loss of $256 million at Optum Health.
Gains and losses on portfolio actions were recorded within operating costs on the Condensed Consolidated Statements of
Operations.
17

-- 19 of 32 --

Restructuring and Other Actions
For the three and nine months ended September 30, 2026, restructuring and other actions included a net decrease in loss
contract reserves of $95 million and $282 million, respectively, and net valuation (losses) gains on equity securities of $(21)
million and $39 million, respectively, while the year-to-date results also included a $400 million contribution to the United
Health Foundation funded by the cash gain on the disposition of an Optum Insight business. By segment, the third quarter
impacts were $62 million and $12 million at Optum Health and Optum Insight, respectively. Year-to-date impacts were $327
million at Optum Insight, partially offset by $248 million at Optum Health. For the three months ended September 30, 2026,
these items decreased investment and other income by $21 million and decreased medical costs by $95 million. For the nine
months ended September 30, 2026, these items increased operating costs by $415 million, partially offset by a $54 million
increase to investment and other income and $282 million decrease in medical costs, as reflected on the Condensed
Consolidated Statements of Operations.
Business Trends
Our businesses participate primarily in the United States health markets. We expect overall spending on health care to continue
to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements,
demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected
by a variety of factors, including macroeconomic conditions and regulatory changes, which could impact our results of
operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs,
including medical care patterns, the mix and health status of people served, inflation and labor market dynamics. We
continually evaluate and adjust our approach in each of the local markets we serve, considering relevant factors, such as product
positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including
minimum medical loss ratio thresholds and similar revenue adjustments. We seek to balance growth and profitability across all
these dimensions.
The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect
broad-based competition to continue as the industry adapts to individual and employer needs. Continued increased medical
costs may impact both future pricing and benefit design, including for our individual exchange products, and may result in
shifts between product categories for our employer benefits. These changes, along with certain regulatory impacts, have
resulted in a reduction in people served and may continue in future periods. Additionally, we have voluntarily pledged to rebate
2026 profits on our individual exchange products to customers as policymakers continue to work to determine how to improve
affordability in this marketplace.
Medicare Advantage funding continues to be pressured, as discussed below in “Regulatory Trends and Uncertainties,” and we
have observed a continued increase in care patterns and health care unit costs as discussed below in “Medical Cost Trends,”
which we have contemplated in both our 2026 and 2027 benefit design approach. Continued funding pressures have resulted in
benefit and pricing actions, causing contraction in our Medicare Advantage membership.
Optum Health’s fully accountable value-based care businesses have been impacted by Medicare funding reductions and have
also seen continued medical cost trend pressures, which may impact future pricing in the markets we continue to participate in.
As a result of increased pricing in response to anticipated care patterns in 2026, the exit from certain markets and decreased
people served through UnitedHealthcare Medicare Advantage offerings, the number of people served under value-based care
arrangements has contracted.
Due to elevated care activity in Medicaid, specifically related to behavioral, pharmacy and home health, there continues to be a
timing mismatch between the health status of people served and state rate updates. The funding and payment rate environment
remains insufficient to meet the health needs of patients and creates the risk of continued downward pressure on Medicaid
margin percentages. We continue to take a prudent, market-sustainable posture for both new business and maintenance of
existing relationships. We continue to advocate for actuarially sound rates commensurate with our medical cost trends and we
remain dedicated to partnering with those states that are committed to the long-term viability of their programs. People served
by Medicaid offerings declined in 2026 due to the exit from one state and reduced Medicaid eligibility.
18

-- 20 of 32 --

Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs.
As expected and contemplated in our benefits design and pricing, we have continued to observe increased care patterns, health
care unit costs and the intensity of services delivered, which are driven by increases in provider pricing and additional services
bundled per visit. Commercial medical cost trend is elevated, in part due to the independent resolution process under the No
Surprises Act and more aggressive billing practices among providers. These trends may continue in future periods. We endeavor
to mitigate medical cost increases by engaging hospitals, physicians and consumers with information and helping them make
clinically sound choices, with the objective of helping them achieve high-quality, affordable care. Additionally, we have
enhanced our audit, clinical policy and payment integrity tools to protect customers and patients from unnecessary costs.
Regulatory Trends and Uncertainties
Medicare Advantage Rates. Medicare Advantage rate notices for numerous years have resulted in industry base rates well
below the industry forward medical cost trend. While the Final Notice for 2027 moved towards the expected industry forward
medical cost trend, it remains below. The compounding impact of multi-year rate shortfalls has created sustained pressure on
the Medicare Advantage program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to
reflect a patient’s health status and care resource needs, have resulted and will continue to result in reduced funding and
potentially benefits for people, especially those with some of the greatest health and social challenges.
As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures
and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make
changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the
member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on
a county-by-county basis where we will offer Medicare Advantage plans.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select third quarter 2026 year-over-year operating comparisons to third quarter 2025 and other
financial results.
• Consolidated revenues were consistent, with UnitedHealthcare and Optum revenues lower by 1% and 3%, respectively.
• UnitedHealthcare served 1.8 million fewer people due to benefit design and pricing actions and reduced Medicaid
eligibility and the exit from one state.
• Consolidated earnings from operations of $6.6 billion compared to $4.3 billion last year.
• Diluted earnings per common share were $4.56.
• Cash flows from operations for the nine months ended September 30, 2026 were $25.1 billion.
19

-- 21 of 32 --

RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per
share data)
Three Months Ended
September 30, Increase/
(Decrease) Nine Months Ended
September 30, Increase/
(Decrease)
2026 2025 2026 vs. 2025 2026 2025 2026 vs. 2025
Revenues:
Premiums......................................... $ 87,078 $ 88,979 $ (1,901) (2) % $ 261,595 $ 263,418 $ (1,823) (1) %
Products........................................... 14,293 13,296 997 7 41,378 39,896 1,482 4
Services ........................................... 10,246 9,754 492 5 30,043 27,765 2,278 8
Investment and other income .......... 1,077 1,132 (55) (5) 3,431 3,273 158 5
Total revenues ......................................... 112,694 113,161 (467) — 336,447 334,352 2,095 1
Operating costs:
Medical costs................................... 76,982 79,958 (2,976) (4) 225,829 231,954 (6,125) (3)
Operating costs................................ 14,369 15,223 (854) (6) 44,027 42,595 1,432 3
Cost of products sold....................... 13,707 12,566 1,141 9 39,905 37,975 1,930 5
Depreciation and amortization ........ 1,073 1,099 (26) (2) 3,142 3,244 (102) (3)
Total operating costs ............................... 106,131 108,846 (2,715) (2) 312,903 315,768 (2,865) (1)
Earnings from operations ........................ 6,563 4,315 2,248 52 23,544 18,584 4,960 27
Interest expense ....................................... (963) (1,003) 40 (4) (2,880) (3,028) 148 (5)
Loss on sale of subsidiary and
subsidiaries held for sale ..................... (76) (83) 7 (8) (209) (139) (70) 50
Earnings before income taxes ................. 5,524 3,229 2,295 71 20,455 15,417 5,038 33
Provision for income taxes...................... (1,224) (686) (538) 78 (4,004) (2,828) (1,176) 42
Net earnings............................................. 4,300 2,543 1,757 69 16,451 12,589 3,862 31
Earnings attributable to noncontrolling
interests................................................ (190) (195) 5 (3) (577) (543) (34) 6
Net earnings attributable to
UnitedHealth Group common
shareholders......................................... $ 4,110 $ 2,348 $ 1,762 75 % $ 15,874 $ 12,046 $ 3,828 32 %
Diluted earnings per share attributable
to UnitedHealth Group common
shareholders ........................................ $ 4.56 $ 2.59 $ 1.97 $ 17.50 $ 13.21 $ 4.29
Medical care ratio (a) .............................. 88.4 % 89.9 % (1.5) % 86.3 % 88.1 % (1.8) %
Operating cost ratio ................................. 12.8 13.5 (0.7) 13.1 12.7 0.4
Operating margin..................................... 5.8 3.8 2.0 7.0 5.6 1.4
Tax rate.................................................... 22.2 21.2 1.0 19.6 18.3 1.3
Net earnings margin (b)........................... 3.6 2.1 1.5 4.7 3.6 1.1
Return on equity (c)................................. 16.7 % 9.9 % 6.8 % 21.8 % 17.0 % 4.8 %
(a) Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.
(b) Net earnings margin attributable to UnitedHealth Group shareholders.
(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’
equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity
balances at the end of each of the quarters in the year presented.
20

-- 22 of 32 --

2026 RESULTS OF OPERATIONS COMPARED TO 2025 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenues
For the three months ended September 30, 2026 revenues decreased due to fewer people served through Medicare Advantage,
commercial risk-based offerings, Medicaid and value-based arrangements at Optum Health, partially offset by pricing trends at
UnitedHealthcare. For the nine months ended September 30, 2026, revenues increased primarily due to pricing trends at
UnitedHealthcare, partially offset by decreased people served through Medicare Advantage, commercial risk-based offerings,
Medicaid and value-based arrangements at Optum Health.
Medical Costs and MCR
Medical costs decreased primarily due to fewer people served across UnitedHealthcare and Optum Health and favorable prior
period reserve development, partially offset by elevated medical cost trend which remains above historical levels and continues
to be affected by higher provider reimbursement under the No Surprises Act and increased service and coding intensity in
commercial.
The MCR decreased due to favorable prior period reserve development, affordability and medical cost management initiatives,
pricing trends and benefit design changes, partially offset by medical cost trend which remains above historical levels and
continues to be affected by higher provider reimbursement under the No Surprises Act and increased service and coding
intensity in commercial.
Operating Cost Ratio
For the three months ended September 30, 2026, the operating cost ratio decreased primarily due to operating cost management
and the revenue impacts of government programs, partially offset by investments in process and technology to drive improved
consumer and care provider experiences and greater operating efficiencies and business mix. For the nine months ended
September 30, 2026, the operating cost ratio increased due to investments in people, process and technology to drive improved
consumer and care provider experiences and greater operating efficiencies and business mix and restructuring and other actions,
partially offset by operating cost management, the revenue impacts of government programs and net portfolio divestitures in
2026.
Reportable Segments
See Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more
information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people
served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted
scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also
allow management and investors to evaluate and understand business mix, including the level and scope of services provided to
people, and pricing trends when comparing the metrics to revenue by segment.
2026 Business Realignment
On January 1, 2026, we realigned certain businesses to respond to changes in the markets we serve and the opportunities that
are emerging as the health system evolves. Optum Financial, including Optum Bank, which was historically included in Optum
Health is now included in Optum Insight. Our reportable segments remain unchanged, with prior period segment financial
information, including people served by Optum, recast to conform to the 2026 presentation.
21

-- 23 of 32 --

The following table presents a summary of the reportable segment financial information:
Three Months Ended
September 30, Increase/
(Decrease) Nine Months Ended
September 30, Increase/
(Decrease)
(in millions, except percentages) 2026 2025 2026 vs. 2025 2026 2025 2026 vs. 2025
Revenues
UnitedHealthcare ................................... $ 86,330 $ 87,070 $ (740) (1) % $ 258,612 $ 257,790 $ 822 — %
Optum Health (a) ........................... 22,910 25,422 (2,512) (10) 70,491 74,984 (4,493) (6)
Optum Insight (a) .......................... 5,474 5,320 154 3 16,001 15,579 422 3
Optum Rx....................................... 39,927 39,679 248 1 113,955 113,270 685 1
Optum eliminations (a) .................. (1,428) (1,244) (184) 15 (4,152) (3,546) (606) 17
Optum .................................................... 66,883 69,177 (2,294) (3) 196,295 200,287 (3,992) (2)
Eliminations ........................................... (40,519) (43,086) 2,567 (6) (118,460) (123,725) 5,265 (4)
Consolidated revenues ........................... $ 112,694 $ 113,161 $ (467) — % $ 336,447 $ 334,352 $ 2,095 1 %
Earnings from operations
UnitedHealthcare ................................... $ 2,831 $ 1,805 $ 1,026 57 % $ 12,467 $ 9,106 $ 3,361 37 %
Optum Health (a) ........................... 735 41 694 nm 3,066 1,881 1,185 63
Optum Insight (a)........................... 1,279 920 359 39 3,611 3,289 322 10
Optum Rx....................................... 1,718 1,549 169 11 4,400 4,308 92 2
Optum .................................................... 3,732 2,510 1,222 49 11,077 9,478 1,599 17
Consolidated earnings from operations . $ 6,563 $ 4,315 $ 2,248 52 % $ 23,544 $ 18,584 $ 4,960 27 %
Operating margin
UnitedHealthcare ................................... 3.3 % 2.1 % 1.2 % 4.8 % 3.5 % 1.3 %
Optum Health (a) ........................... 3.2 0.2 3.0 4.3 2.5 1.8
Optum Insight (a)........................... 23.4 17.3 6.1 22.6 21.1 1.5
Optum Rx....................................... 4.3 3.9 0.4 3.9 3.8 0.1
Optum .................................................... 5.6 3.6 2.0 5.6 4.7 0.9
Consolidated operating margin.............. 5.8 % 3.8 % 2.0 % 7.0 % 5.6 % 1.4 %
nm = not meaningful
(a) Prior period amounts have been recast to reflect the realignment of Optum Financial.
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
Three Months Ended
September 30, Increase/
(Decrease) Nine Months Ended
September 30, Increase/
(Decrease)
(in millions, except percentages) 2026 2025 2026 vs. 2025 2026 2025 2026 vs. 2025
UnitedHealthcare Employer & Individual - Domestic ...... $ 19,223 $ 19,049 $ 174 1 % $ 57,477 $ 57,065 $ 412 1 %
UnitedHealthcare Employer & Individual - Global........... 985 826 159 19 2,841 2,427 414 17
UnitedHealthcare Employer & Individual - Total ..... 20,208 19,875 333 2 60,318 59,492 826 1
UnitedHealthcare Medicare & Retirement ........................ 42,420 43,356 (936) (2) 126,892 127,684 (792) (1)
UnitedHealthcare Community & State .............................. 23,702 23,839 (137) (1) 71,402 70,614 788 1
Total UnitedHealthcare revenues............................... $ 86,330 $ 87,070 $ (740) (1) % $ 258,612 $ 257,790 $ 822 — %
22

-- 24 of 32 --

The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment
and funding arrangement:
September 30, Increase/(Decrease)
(in thousands, except percentages) 2026 2025 2026 vs. 2025
Commercial:
Risk-based................................................................................................................................. 7,575 8,440 (865) (10) %
Fee-based .................................................................................................................................. 22,180 21,490 690 3
Total Commercial ................................................................................................................... 29,755 29,930 (175) (1)
Medicare Advantage .................................................................................................................... 7,605 8,435 (830) (10)
Medicaid ...................................................................................................................................... 6,695 7,460 (765) (10)
Medicare Supplement (Standardized).......................................................................................... 4,245 4,300 (55) (1)
Total Community and Senior.................................................................................................. 18,545 20,195 (1,650) (8)
Total UnitedHealthcare - Medical .......................................................................................... 48,300 50,125 (1,825) (4) %
Supplemental Data:
Medicare Part D stand-alone................................................................................................... 2,690 2,795 (105) (4) %
South American businesses held for sale................................................................................ 1,140 1,160 (20) (2) %
For the three months ended September 30, 2026, UnitedHealthcare’s revenues decreased due to the contraction in people served
through Medicare Advantage, risk-based commercial offerings and Medicaid offerings, partially offset by pricing trends and
actions, including increased Medicaid rates and growth in people served through fee-based commercial offerings. For the nine
months ended September 30, 2026, revenues increased due to pricing trends and actions, including increased Medicaid rates,
and growth in people served through fee-based commercial offerings, partially offset by the contraction in people served
through Medicare Advantage, risk-based commercial offerings and Medicaid offerings, and our pledge to rebate profits on our
individual exchange products to customers. Earnings from operations increased due to the revenue drivers discussed above, as
well as favorable prior period reserve development, and affordability and medical cost management initiatives, partially offset
by investments to support future growth.
Optum
Total revenues decreased due to Optum Health, partially offset by growth in Optum Rx and Optum Insight. Earnings from
operations increased due to earnings growth across Optum. The results by segment were as follows:
Optum Health
Revenues at Optum Health decreased primarily due to fewer patients served under value-based arrangements and the impact of
dispositions, partially offset by the impact of business combinations. Earnings from operations increased due to cost
management, pricing trends, increased favorable reserve development and a net decrease in loss contract reserves, partially
offset by continued elevated medical cost trends. Earnings from operations for the three months ended September 30, 2026, also
increased due to the impact of net portfolio divestitures. For the nine months ended September 30, 2026, the increase in Optum
Health earnings from operations was partially offset by the impact of net portfolio divestitures. Optum Health served
approximately 92 million people and 93 million people as of September 30, 2026 and September 30, 2025, respectively.
Optum Insight
Revenues and earnings from operations at Optum Insight increased due to elevated investment and other income and growth in
business and technology services. Earnings from operations for the nine months ended September 30, 2026 also increased due
to net portfolio divestitures in 2026, partially offset by the impacts of restructuring and other actions and investments to support
future growth.
Optum Rx
Revenues at Optum Rx increased due to growth in retail and specialty pharmacy, partially offset by reduced script volume as a
result of the contraction in people served at UnitedHealthcare. Earnings from operations increased due to growth in specialty
pharmacy, partially offset by the impact of reduced script volumes. Optum Rx fulfilled 393 million and 414 million adjusted
scripts in the third quarters of 2026 and 2025, respectively.
23

-- 25 of 32 --

LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
Nine Months Ended
September 30, Increase/
(Decrease)
(in millions) 2026 2025 2026 vs. 2025
Sources of cash:
Cash provided by operating activities.......................................................................................... $ 25,087 $ 18,589 $ 6,498
Issuances of short-term borrowings and long-term debt, net of repayments............................... — 2,438 (2,438)
Cash received from dispositions and other strategic transactions, net......................................... 1,113 214 899
Proceeds from common stock issuances...................................................................................... 599 803 (204)
Sales and maturities of investments, net of purchases................................................................. — 1,657 (1,657)
Repayments of care provider loans - cyberattack ........................................................................ 282 1,543 (1,261)
Other ............................................................................................................................................ 464 — 464
Total sources of cash............................................................................................................................ 27,545 25,244 2,301
Uses of cash:
Cash dividends paid ..................................................................................................................... (6,170) (5,914) (256)
Common stock repurchases ......................................................................................................... (5,031) (5,545) 514
Repayments of short-term borrowings and long-term debt, net of issuances.............................. (3,075) — (3,075)
Cash paid for acquisitions and other transactions, net of cash assumed...................................... (1,538) (4,436) 2,898
Purchases of investments, net of sales and maturities ................................................................. (4,486) — (4,486)
Purchases of property, equipment and capitalized software........................................................ (2,421) (2,674) 253
Originations and purchases of loans, net of repayments and maturities...................................... (2,232) (2,288) 56
Customer funds administered ...................................................................................................... (743) (1,792) 1,049
Other ............................................................................................................................................ (613) (693) 80
Total uses of cash................................................................................................................................. (26,309) (23,342) (2,967)
Effect of exchange rate changes on cash and cash equivalents ........................................................... (11) 25 (36)
Increase in cash and cash equivalents, including cash within businesses held for sale....................... $ 1,225 $ 1,927 $ (702)
Net change in cash within businesses held for sale ............................................................................. 255 (29) 284
Net increase in cash and cash equivalents ........................................................................................... $ 1,480 $ 1,898 $ (418)
2026 Cash Flows Compared to 2025 Cash Flows
Increased cash flows provided by operating activities were driven by increased earnings, timing of government payments, other
favorable working capital dynamics and legislative changes from the Inflation Reduction Act impacting pharmacy rebates.
Other significant changes in sources or uses of cash year-over-year included decreased cash paid for acquisitions, increased
customer funds administered, increased cash received from dispositions and decreased share repurchases, offset by increased
net purchases of investments, decreased issuances and increased repayments of short-term borrowings and long-term debt and
decreased repayments of care provider loans.
Financial Condition
As of September 30, 2026, our cash, cash equivalent, available-for-sale debt securities and marketable equity securities
balances of $78.3 billion included approximately $25.8 billion of cash and cash equivalents (of which $1.2 billion was available
for general corporate use), $50.3 billion of debt securities and $2.2 billion of investments in marketable equity securities.
Additionally, we had $11.5 billion of loan receivables as of September 30, 2026. Given the significant portion of our portfolio
held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a
material impact on our liquidity or capital position.
Our available-for-sale debt securities portfolio had a weighted-average duration of 4.3 years and a weighted-average credit
rating of “Double A” as of September 30, 2026. When multiple credit ratings are available for an individual security, the
average of the available ratings is used to determine the weighted-average credit rating.
24

-- 26 of 32 --

Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital
resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2025 was disclosed in Part II, Item 7,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2025 10-K. During the nine
months ended September 30, 2026, there were no material changes to this previously disclosed information outside the ordinary
course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We
continually evaluate opportunities to expand our operations, including through internal development of new products, programs
and technology applications and business combinations.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing
program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for
general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of the Notes to
the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2025 10-
K. As of September 30, 2026, we were in compliance with the various covenants under our bank credit facilities.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as to
meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information
on our long-term debt, see Note 5 of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of
this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and
Supplementary Data” in our 2025 10-K.
Credit Ratings. Our credit ratings as of September 30, 2026 were as follows:
Moody’s S&P Global Fitch A.M. Best
Ratings Outlook Ratings Outlook Ratings Outlook Ratings Outlook
Senior unsecured debt.......................... A2 Negative A+ Negative A Negative A- Stable
Commercial paper................................ P-1 n/a A-1 n/a F1 n/a AMB-1 n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating
cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic
and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase
the cost of borrowing for us or limit our access to capital.
Regulatory Capital. Our regulated insurance and HMO subsidiaries have specified levels of statutory capital required to be
maintained, which fluctuates based upon premiums received and the MCR of the regulated subsidiary. We have various
agreements with reinsurers that could limit our risk of loss under certain circumstances, thus reducing our capital and surplus
requirements. These agreements do not qualify for reinsurance accounting and are therefore accounted for under deposit
accounting.
Share Repurchase Program. During the nine months ended September 30, 2026, we repurchased approximately 13.8 million
shares at an average price of $359.55 per share, including 6.4 million shares purchased at an average price of $312.73 per share
pursuant to forward share repurchase contracts that were settled on July 1, 2026. See Note 6 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report for more information on the Company’s forward
share repurchase contracts.
As of September 30, 2026, we had Board of Directors’ authorization to purchase up to 7.2 million shares of our common stock.
The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized
number of shares which may be repurchased under the program.
Dividends. In June 2026, our Board of Directors increased our quarterly cash dividend to an annual rate of $9.28 compared to
$8.84 per share which we had paid since June 2025. For more information on our dividend, see Note 6 of Notes to the
Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8,
“Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” included in Part II, Item 7 in our 2025 10-K.
25

-- 27 of 32 --

RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated
Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates,
which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and
estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent
liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends.
On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results,
however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical
accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included
in Part II, Item 7 in our 2025 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2025 10-
K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements
which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,”
“expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify
forward-looking statements. These statements may contain information about financial prospects, economic conditions and
trends and involve risks and uncertainties. Actual results could differ materially from those that management expects,
depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs;
new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data
security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received
under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data
validation audits; our ability to successfully execute initiatives designed to simplify and improve the consumer healthcare
experience; our ability to effectively execute our value-based care strategies; the DOJ’s legal actions concerning our
participation in the Medicare program; our ability to maintain and achieve improvement in quality scores impacting revenue;
failure to maintain effective and efficient information systems or if our technology products do not operate as intended; risks
and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability
to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve
targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care
payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations; increases
in costs and other liabilities associated with litigation, government investigations, audits or reviews; risks and uncertainties
associated with our increasing use of artificial intelligence and other emerging technologies; failure to complete, manage or
integrate strategic transactions; risks and uncertainties associated with the sale of our remaining operations in South America;
risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other
extreme events; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment
portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases,
software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated
subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio
at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.
The above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial
condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K.
By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks,
uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations
expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-
looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-
looking statements, except as required by law.
26

-- 28 of 32 --

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt
across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of
interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in
comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1%
point or 2% points as of September 30, 2026 on our investment income and interest expense per annum, and the fair value of
our investments and debt (in millions, except percentages):
September 30, 2026
Increase (Decrease) in Market Interest Rate
Investment
Income Per
Annum
Interest
Expense Per
Annum Fair Value of
Financial Assets Fair Value of
Financial Liabilities
2 %................................................................................... $ 738 $ 616 $ (4,440) $ (7,380)
1........................................................................................ 369 308 (2,280) (4,010)
(1) ..................................................................................... (369) (294) 2,361 4,812
(2) ..................................................................................... (738) (583) 4,751 10,637
Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on
the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.
ITEM 4. CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in
reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time
periods specified in SEC rules and forms, and (ii) accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the
participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our
disclosure controls and procedures as of September 30, 2026. Based upon that evaluation, our Chief Executive Officer and
Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level
as of September 30, 2026.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2026 that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
27

-- 29 of 32 --

PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item
1A, “Risk Factors” of our 2025 10-K, which could materially affect our business, financial condition or future results. The risks
described in our 2025 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that
we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2025 10-K.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities (a)
Third Quarter 2026
For the Month Ended Total Number of
Shares Purchased Average Price Paid
Per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares That May Yet Be
Purchased Under The
Plans or Programs
(in millions) (in millions) (in millions)
July 31, 2026.......................................... 1.5 $ 424.31 1.5 9.1
August 31, 2026..................................... 1.4 402.79 1.4 7.7
September 30, 2026 ............................... 0.5 388.67 0.5 7.2
Total ....................................................... 3.4 $ 410.01 3.4
(a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In November 2026,
the Board of Directors amended our share repurchase program to authorize the repurchase of up to 50 million shares of our common stock in open
market purchases or other types of transactions (including prepaid or structured repurchase programs), in addition to all remaining shares authorized to
be repurchased under the Board’s 2024 renewal of the program. There is no established expiration date for the program. The Board of Directors from
time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the
program.
ITEM 5. OTHER INFORMATION
Trading Arrangements
During the quarter ended September 30, 2026, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under
the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company
securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule
10b5-1 trading arrangement.
28

-- 30 of 32 --

ITEM 6. EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company
files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the
Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the
Company’s Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2 Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective November 6, 2025 (incorporated
by reference to Exhibit 3.1 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on
November 13, 2025)
4.1 Amended and Restated Indenture, dated as of April 27, 2023, between UnitedHealth Group Incorporated and
Wilmington Trust Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth
Group Incorporated’s Current Report on Form 8-K filed on April 28, 2023)
4.2 Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National
Association (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3,
SEC File Number 333-149031, filed on February 4, 2008)
4.3 Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth Group Incorporated and U.S. Bank
Trust Company, National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated
by reference to Exhibit 4.1 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on April
24, 2023)
31.1 Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its
XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
________________
* Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The
Company will furnish copies thereof to the SEC upon request.
29

-- 31 of 32 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/s/ STEPHEN HEMSLEY Chair and Chief Executive Officer
(principal executive officer)
Dated: November 3, 2026
Stephen Hemsley
/s/ WAYNE DEVEYDT Chief Financial Officer
(principal financial officer) Dated: November 3, 2026
Wayne DeVeydt
/s/ DENNIS STANKIEWICZ Chief Accounting Officer
(principal accounting officer)
Dated: November 3, 2026
Dennis Stankiewicz
30

-- 32 of 32 --